升血方剂对结直肠癌化疗患者免疫功能及骨髓抑制的影响

摘要

Objective To explore the influence of the old Chinese national match the experience of haplostele liters of blood prescription of chemotherapy for colorectal cancer patients with immune function and bone marrow suppression .Methods 94 cases of metastatic nodes in patients with rectal cancer treated in our hospital from February 2011 to June 2015 were selected as the re‐search object ,and were randomly divided into observation group and control group according to different regimen in the treatment , with 47 cases in each group .Patients in control group was treated with conventional XELON chemotherapy ,and patients in the ob‐servation group recieved rise blood prescription treatment based on the chemotherapy in the control group .The immune function and bone marrow suppression situation in both groups were observed after two treatment cycles .Results The stable rate of the obser‐vation group was 42 .55% ,significantly higher than that of the control group (P<0 .05);the CD4+ /,CD8+ CD8+ and NK cells were significantly higher than those in the control group (P<0 .05) ,while those of the control group was significantly higher than that in control group (P>0 .05);the CD4+ /,CD8+ CD8+ and CD4+ /cells were significantly higher than those in control group (P<0 .05);The incidence rate of KPS in the observation group and control group was 70 .21% ,70 .21% ,17 .02% ,14 .89% , 87 .23% ,25 .53% and 23 .40% respectively .The KPS score of the observation group and the control group were significantly higher than that in control group (P<0 .05) ,and the G‐CSF in the observation group was significantly higher than that in control group (P<0 .05) .Conclusion The treatment of advanced metastatic colorectal cancer patients in the course of chemotherapy to give rise to blood formula can effectively improve the patient′s immune function ,reduce the bone marrow suppression effect ,improve the quality of life ,and it is worthy of clinical application .%目的：探讨升血方剂对结直肠癌化疗患者免疫功能及骨髓抑制的影响。方法以2011年2月至2015年6月在贵州省中医院肛肠科住院治疗的94例转移性结直肠癌患者为研究对象，根据治疗方案的不同分成观察组和对照组，每组各47例，对照组采用常规的XELON方案进行化疗，观察组在对照组化疗方案的基础上给予升血方剂治疗，治疗两个周期后检测两组治疗后的免疫功能及骨髓抑制情况。结果观察组治疗后稳定率为63．83％，明显高于对照组42．55％（ P＜0．05）；观察组治疗后CD4＋、CD4＋／CD8＋及NK细胞活性明显高于对照组（P＜0．05），而对照组治疗后CD4＋、CD4＋／CD8＋及NK细胞活性于治疗前相比差异无统计学意义（P＞0．05）；观察组治疗后CD4＋、CD4＋／CD8＋及 NK细胞活性明显高于对照组治疗后CD4＋、CD4＋／CD8＋及NK细胞活性（P＜0．05）；观察组治疗后白细胞、中性粒细胞、血小板、血红蛋白减少的发生率分别是70．21％、70．21％、17．02％、14．89％，低于对照组对照组白细胞、中性粒细胞、血小板、血红蛋白减少的发生率，分别是85．11％、87．23％、25．53％、23．40％，观察组白细胞、中性粒细胞减少发生率明显低于对照组（ P＜0．05）；观察组和对照组治疗后生活质量K PS评分均高于治疗前（P＜0．05）；观察组治疗后生活质量KPS评分明显高于对照组治疗后（P＜0．05），观察组G‐CSF使用率低于对照组（P＜0．05）。结论升血方剂能有效提高晚期转移性结直肠癌患者的免疫功能，减轻骨髓抑制作用，提高生活质量。